JPRN-C000000161未知1 期
Phase I/II study of adoptive immunotherapy using predetermined minor histocompatibility antigen-specific cytotoxic T cells for patients with high-risk leukemia that relapsed following allogeneic hematopoietic stem cell transplantation. - Cellular adoptive immunotherapy targeting predetermined minor histocompatibility antigens for the treatment of patients with relapsed leukemia following transplantation.
适应症
试验速览
- 阶段
- 1 期
- 入组人数
- 30
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18years-old 至 65years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1) CNS involvement or uncontrollable extramedullary disease. 2) Severe infections (including active tuberculosis) or double cancer 3) Patients with organ toxicity as follows: (a) T.Bil >= 1.5 mg/dl, (b) GOT, GPT >= 2.5 x N (upper normal limit of individual institutions), (c) serum creatine >= 1.5 x N, 24-h Ccr =< 60 ml/min, (d) PaO2 < 60 mmHg, (e) ejection fraction <50%, (f) abnormal ECG (ischemic change or arrhythmia requiring treatment) 4) Uncontrolable HT 5) One of the following: positive HBs antigen, seropositive to HCV, seropositive to HIV, seropositive to HTLV-1, seropositive to STS 6) Patients treated with major tranquilizer or antidepressant 7) Patients inappropriate for transplantation with reasons other than above.
研究者
相似试验
未知
1 期
Phase I/II study of adoptive immunotherapy using cytotoxic T cells specific for minor histocompatibility antigen restricted to hematopoietic cells for patients with high-risk leukemia that relapsed following allogeneic hematopoietic stem cell transplantatio1) RAEB, CMML 2) AML or ALL in induction failure or beyond first remission 3) Ph/p190-positive ALL at any stage 4) imatinib-resistant CMJPRN-C000000162Aichi Cancer Center30
已完成
1 期
A phase 1 study of adoptive immunotherapy using autologous RNF43 peptide pulse dendritic cells and RNF43 peptide specifically activated lymphocytes in patients with advanced solid tumorsadvanced solid tumors which already have finished available standard therapies.JPRN-UMIN000003945Kyushu University Hospital10
已完成
不适用
Phase I/IIa Study of Adoptive Immunotherapy Comprising 2-Methyl-3-Butenyl-1-Pyrophosphate-Stimulated Gamma Delta T Cells in Patients With PSA biochemical failure after radical prostatectomy.JPRN-UMIN000006617Tokyo Women's Medical University10
进行中（未招募）
1 期
Clinical study with autologous CIK cells for patients with advanced and uresectable sarcomapatients with advanced and non-resectable sarcomaMedDRA version: 20.0Level: PTClassification code 10039491Term: SarcomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2017-002257-11-ITAOU CITTA' DELLA SALUTE E DELLA SCIENZA DI TORINO35
已完成
不适用
Phase II Study of Adoptive Immunotherapy Comprising 2-Methyl-3-Butenyl-1-Pyrophosphate-Stimulated Gamma Delta T Cells, Teceleukin, and Zoledronic acid in Patients With Stage IV Renal Cell CarcinomaCytokine refractory Renal cell carcinomaJPRN-UMIN000004482Tokyo Women's Medical University35